The city of Fresno, California, currently has 2 active clinical trials seeking participants for Pulmonary Fibrosis research studies.
A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
Recruiting
The main purpose of the study is to evaluate the efficacy of vixarelimab compared with placebo on lung function in participants with idiopathic pulmonary fibrosis (IPF) and in participants with systemic sclerosis-associated interstitial lung disease (SSc-ILD). Participants who complete 52-weeks of treatment in the Double-blind Treatment (DBT) period can choose to enroll in the optional Open-label Extension (OLE) period to receive treatment with vixarelimab for another 52 weeks. Cohort 1 has com... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
04/14/2025
Locations: University of California, San Francisco-Fresno, Fresno, California
Conditions: Idiopathic Pulmonary Fibrosis, Systemic Sclerosis With Lung Involvement
A Study to Investigate Leramistat in Patients With IPF
Recruiting
To compare the effect of daily oral dosing of leramistat over 12 weeks with placebo in participants aged 40 years or older with idiopathic pulmonary fibrosis (IPF).
Gender:
ALL
Ages:
40 years and above
Trial Updated:
02/16/2024
Locations: UCSF Fresno, Fresno, California
Conditions: Idiopathic Pulmonary Fibrosis